Skip to Main Content

Another embarrassing and costly blunder has befallen Celgene.

The Food and Drug Administration is refusing to review ozanimod, an experimental treatment for multiple sclerosis and Celgene’s most important pipeline product, the company said Tuesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.